| Date Filed | Type | Description |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2023 |
4
| Lask Alisa (Director) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 12,000 shares
@ $0.49, valued at
$5.9k
|
|
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/11/2023 |
4
| COWAN GREGORY L (Director) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Granted 40,000 shares
@ $0 |
|
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/22/2023 |
4
| Schaub James (EVP and COO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 5,577 shares
@ $0.87, valued at
$4.9k
|
|
| 05/22/2023 |
4
| Klein Christopher (General Counsel & Secretary) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 5,447 shares
@ $0.87, valued at
$4.7k
|
|
| 01/30/2023 |
4
| Burgstahler David F (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Disposed of 1,032,995 shares
@ $0 |
|
| 01/30/2023 |
4
| Venkataraman Sriram (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Disposed of 1,032,995 shares
@ $0 |
|
| 01/30/2023 |
4
| Avista Capital Partners III GP, L.P. (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Disposed of 1,032,995 shares
@ $0 |
|
| 01/26/2023 |
4
| Klein Christopher (General Counsel & Secretary) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,608 shares
@ $1.26, valued at
$12.1k
|
|
| 01/26/2023 |
4
| Schaub James (EVP and COO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,608 shares
@ $1.26, valued at
$12.1k
|
|
| 08/12/2022 |
4
| Lask Alisa (Director) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Granted 75,000 shares
@ $0 |
|
| 08/12/2022 |
3
| Lask Alisa (Director) has filed a Form 3 on RVL Pharmaceuticals plc |
| 08/12/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/09/2022 |
4
| Schaub James (EVP and COO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Bought 150,000 shares
@ $1.55, valued at
$232.5k
|
|
| 08/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/09/2022 |
4
| Burgstahler David F (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Bought 8,000,000 shares
@ $1.55, valued at
$12.4M
|
|
| 08/09/2022 |
4
| Venkataraman Sriram (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Bought 8,000,000 shares
@ $1.55, valued at
$12.4M
|
|
| 08/09/2022 |
4
| Avista Healthcare Partners, L.P. (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Bought 8,000,000 shares
@ $1.55, valued at
$12.4M
|
|
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/22/2022 |
3
| DePetris Michael (Principal Accounting Officer) has filed a Form 3 on RVL Pharmaceuticals plc |
| 01/26/2022 |
4
| Einhorn Andrew J. (CFO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,607 shares
@ $1.13, valued at
$10.9k
|
|
| 01/26/2022 |
4
| Klein Christopher (General Counsel & Secretary) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,607 shares
@ $1.13, valued at
$10.9k
|
|
| 01/26/2022 |
4
| deVries Tina Marie (EVP, Research & Development) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,607 shares
@ $1.13, valued at
$10.9k
|
|
| 01/26/2022 |
4
| Schaub James (EVP and COO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 9,607 shares
@ $1.13, valued at
$10.9k
|
|
| 12/20/2021 |
4
| Schaub James (EVP and COO) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Bought 93,800 shares
@ $1.07, valued at
$100.4k
|
|
| 11/08/2021 |
4
| deVries Tina Marie (EVP, Research & Development) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Granted 216,944 options to buy
@ $1.8, valued at
$390.5k
|
|
| 11/08/2021 |
4
| Schaub James (EVP and COO) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Granted 249,814 options to buy
@ $1.8, valued at
$449.7k
|
|
| 11/08/2021 |
4
| Klein Christopher (General Counsel & Secretary) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Granted 249,814 options to buy
@ $1.8, valued at
$449.7k
|
|
| 11/08/2021 |
4
| Einhorn Andrew J. (CFO) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Granted 249,814 options to buy
@ $1.8, valued at
$449.7k
|
|
| 11/08/2021 |
4
| MARKISON BRIAN A (CEO) has filed a Form 4 on Osmotica Pharmaceuticals plc|
Txns:
| Granted 615,000 options to buy
@ $1.8, valued at
$1.1M
|
|
|